We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Pragmatic Support Improved Outcomes for HIV-Infected Drug Users

Gold pills spell out the letters HIV, surrounded by pill packets.
Credit: Miguel Á. Padriñán/ Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

New research from Boston Medical Center found that providing pragmatic support, specifically rapid access to antiretroviral therapy, pharmacotherapy for opioid use disorder, and strengths-based case management, improved treatment outcomes for people with HIV who inject drugs in St. Petersburg, Russia. Published in The Lancet HIV, researchers from the Linking Infectious and Narcology Care – Part II (LINC-II) trial highlight that the odds of achieving viral load suppression at 12 months are 3 times higher for participants randomized to the intervention group.

Russia continues to have the largest HIV epidemic in Europe, with the total number of people with HIV exceeding 1.4 million and over 71,000 new infections in 2021. Among the newly diagnosed Russian people with HIV in 2021, 28% reported past injection drug use. Strengthening the HIV response in Russia requires engaging people who inject drugs in treatment. Antiretroviral therapy coverage in Russia is low for people with HIV who inject drugs, and HIV and addiction treatment in Russia are not well integrated.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
While the study’s focus was on people with HIV who inject drugs in St. Petersburg, Russia, the implications of early ART initiation extend far beyond national borders.

“We hope to improve the treatment for people with HIV who inject drugs by addressing barriers for accessing both HIV and addiction care, a challenge both in Russia and other countries with this population,” said senior author Jeffrey Samet, MD, MA, MPH, a primary care physician at Boston Medical Center and John Noble, M.D. Professor in General Internal Medicine at Boston University Chobanian & Avedisian School of Medicine. “Scaling up the LINC-II model is one strategy to advance the UNAIDS goal of ending the HIV epidemic.”

These findings support the usefulness of expanding the LINC-II approach in Russia, given both the positive outcomes of the findings and the high receptivity by participants to elements of the intervention.

Researchers believe that although significant improvements were achieved with the intervention, the results do highlight the great challenge of effectively treating people with HIV who inject drugs.


Reference: Samet JH, Blokhina E, Cheng DM, et al. Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial. Lancet HIV. 2023;10(9):e578-e587. doi: 10.1016/S2352-3018(23)00143-1

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.